# Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)

> **NCT00956787** · PHASE2 · UNKNOWN · sponsor: **Arno Therapeutics** · enrollment: 25 (estimated)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)

## Key facts

- **NCT ID:** NCT00956787
- **Lead sponsor:** Arno Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-06
- **Primary completion:** 2014-07
- **Final completion:** 2014-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00956787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00956787, "Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00956787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*